McKesson (MCK)
(Delayed Data from NYSE)
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Abbott (ABT) Diagnostic and Nutrition Arms Grow Worldwide
by Zacks Equity Research
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline
by Zacks Equity Research
IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.
McKesson (MCK) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption
by Zacks Equity Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.
LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.
BD (BDX) Partners With Retailers for At-Home COVID-19 Test
by Zacks Equity Research
BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.
Thermo Fisher (TMO) Releases New Update for Omicron Detection
by Zacks Equity Research
Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.
Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM
by Zacks Equity Research
CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.
Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.
Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M
by Zacks Equity Research
Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Accuray's (ARAY) CyberKnife System Gets Shonin Approval
by Zacks Equity Research
Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Ecolab (ECL) Stock Right Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction from a solid product portfolio and segmental strength. However, segmental weakness remains a woe.
Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering
by Zacks Equity Research
Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.